Key result
Ticlopidine 250 mg twice daily yielded identical minimum plasma concentrations in chronic renal failure patients and healthy volunteers (0.35 vs 0.36 mg/L), indicating no dosage change is required.
Why the study?
Does chronic renal failure alter the pharmacokinetics and antiplatelet effect of ticlopidine compared to healthy volunteers?
Population
13 participants: 6 patients with chronic renal failure not on dialysis and 7 matched healthy volunteers.
Comparison
Ticlopidine 250 mg oral twice daily for 36 days. vs Healthy volunteers receiving the same…
Design
Cohort
Follow-up
36 days
Authors
Loading...
May support no ticlopidine dose adjustment in chronic renal failure; leaves open confirmation in larger studies.
Does chronic renal failure alter the pharmacokinetics and antiplatelet effect of ticlopidine compared to healthy volunteers?
Absolute Event Rate: 0.35% vs 0.36%
Ticlopidine pharmacokinetics and antiplatelet effects are sufficiently similar between patients with chronic renal failure and healthy volunteers that no dosage adjustment is required.
Buur et al. (1997) studied Chronic renal failure (n=13). Ticlopidine vs. Healthy volunteers was evaluated on Minimum concentrations in plasma of unchanged ticlopidine at day 36 (mg/L). Ticlopidine 250 mg twice daily yielded identical minimum plasma concentrations in chronic renal failure patients and healthy volunteers (0.35 vs 0.36 mg/L), indicating no dosage change is required.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: